| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.33B | +25.0% |
| Gross profit | ¥0.10B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | +21.1% |
| Gross margin | 30.5% | Net margin 7.9% |
| Revenue Q/Q | -6.6% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.23B | 69.5% |
| R&D | ¥0.02B | 5.2% |
| SG&A | ¥0.03B | 9.8% |
| Tax & other | ¥0.00B | 0.7% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金冠股份 ・ 雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies